• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用维布妥昔单抗治疗CD30淋巴瘤后发生巨细胞病毒感染伴视网膜炎

Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30 Lymphoma.

作者信息

Tudesq Jean-Jacques, Vincent Laure, Lebrun Julie, Hicheri Yosr, Gabellier Ludovic, Busetto Timothé, Merle Corinne, Fegueux Nathalie, Ceballos Patrice, Quittet Philippe, Navarro Robert, Hillaire-Buys Dominique, Cartron Guillaume

机构信息

Département d'Hématologie Clinique.

Département de Réanimation Médicale et des Brûlés.

出版信息

Open Forum Infect Dis. 2017 Apr 5;4(2):ofx091. doi: 10.1093/ofid/ofx091. eCollection 2017 Spring.

DOI:10.1093/ofid/ofx091
PMID:28638848
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5473439/
Abstract

Brentuximab vedotin is an antibody-conjugated chemotherapy targeting CD30 indicated in treatment of several lymphomas. We report the first 3 cases of cytomegalovirus severe infections with retinitis following this treatment. Evolution was favorable, but relapse occurred after treatment rechallenge. We suggest vigilance about cytomegalovirus in patients treated with brentuximab vedotin.

摘要

本妥昔单抗是一种靶向CD30的抗体偶联化疗药物,用于治疗多种淋巴瘤。我们报告了首例接受该治疗后发生巨细胞病毒严重感染并伴有视网膜炎的3例病例。病情进展良好,但再次治疗后复发。我们建议对接受本妥昔单抗治疗的患者警惕巨细胞病毒感染。

相似文献

1
Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30 Lymphoma.用维布妥昔单抗治疗CD30淋巴瘤后发生巨细胞病毒感染伴视网膜炎
Open Forum Infect Dis. 2017 Apr 5;4(2):ofx091. doi: 10.1093/ofid/ofx091. eCollection 2017 Spring.
2
Brentuximab vedotin in systemic T-cell lymphoma.本妥昔单抗维达汀治疗系统性 T 细胞淋巴瘤。
Expert Opin Biol Ther. 2012 May;12(5):623-32. doi: 10.1517/14712598.2012.670216. Epub 2012 Mar 20.
3
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.本妥昔单抗维迪昔联合 ABVD 或 AVD 方案用于治疗初诊霍奇金淋巴瘤患者的 1 期、开放标签、剂量递增研究。
Lancet Oncol. 2013 Dec;14(13):1348-56. doi: 10.1016/S1470-2045(13)70501-1. Epub 2013 Nov 15.
4
Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.用于复发或难治性霍奇金淋巴瘤的本妥昔单抗
Drug Des Devel Ther. 2015 Mar 23;9:1729-33. doi: 10.2147/DDDT.S82007. eCollection 2015.
5
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.欧洲药品管理局对用于治疗复发或难治性CD30+霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤成年患者的本妥昔单抗(安适利)的审评:人用药品委员会科学评估总结
Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.
6
Brentuximab vedotin for the treatment of CD30+ lymphomas.本妥昔单抗维达汀治疗 CD30+淋巴瘤。
Immunotherapy. 2011 Apr;3(4):475-85. doi: 10.2217/imt.11.15.
7
Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.在用维布妥昔单抗治疗的复发性皮肤CD30+淋巴样肿瘤中,通过免疫组织化学检测发现CD30表达存在可变缺失。
J Cutan Pathol. 2019 Nov;46(11):823-829. doi: 10.1111/cup.13545. Epub 2019 Aug 2.
8
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.本妥昔单抗维泊妥珠单抗作为自体造血干细胞移植后巩固治疗在有复发或进展风险的霍奇金淋巴瘤患者中的应用(AETHERA):一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2015 May 9;385(9980):1853-62. doi: 10.1016/S0140-6736(15)60165-9. Epub 2015 Mar 19.
9
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.维布妥昔单抗治疗儿童复发或难治性霍奇金淋巴瘤及间变性大细胞淋巴瘤:一项多中心、开放标签的1/2期研究。
Lancet Haematol. 2018 Oct;5(10):e450-e461. doi: 10.1016/S2352-3026(18)30153-4.
10
Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.本妥昔单抗维布妥昔单抗:一种靶向 CD30 的抗体-细胞毒性药物偶联物。
Pharmacotherapy. 2013 Jan;33(1):93-104. doi: 10.1002/phar.1170.

引用本文的文献

1
Cytomegalovirus Lymphadenitis Mimicking Hodgkin Lymphoma Relapse.酷似霍奇金淋巴瘤复发的巨细胞病毒淋巴结炎
Cureus. 2025 Jan 19;17(1):e77649. doi: 10.7759/cureus.77649. eCollection 2025 Jan.
2
Insights into uveitis from Brentuximab vedotin in refractory Hodgkin's lymphoma: a case report and brief review.从维布妥昔单抗治疗难治性霍奇金淋巴瘤中洞察葡萄膜炎:一例报告及简要综述
Front Oncol. 2024 Aug 5;14:1419145. doi: 10.3389/fonc.2024.1419145. eCollection 2024.
3
Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.

本文引用的文献

1
Cytomegalovirus Retinitis: A Review.巨细胞病毒性视网膜炎:综述
J Ocul Pharmacol Ther. 2017 May;33(4):224-234. doi: 10.1089/jop.2016.0140. Epub 2017 Mar 29.
2
Atypical cytomegalovirus retinitis in non-Hodgkin's lymphoma.非霍奇金淋巴瘤中的非典型巨细胞病毒性视网膜炎
BMJ Case Rep. 2015 Aug 3;2015:bcr2015210812. doi: 10.1136/bcr-2015-210812.
3
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.美国食品和药物管理局批准概要:本妥昔单抗维泊妥珠单抗用于治疗复发的霍奇金淋巴瘤或复发的系统性间变性大细胞淋巴瘤。
血液系统恶性肿瘤中使用靶向治疗继发严重感染的风险
Cureus. 2024 Jan 10;16(1):e52050. doi: 10.7759/cureus.52050. eCollection 2024 Jan.
4
Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies.血液系统恶性肿瘤中使用靶向治疗继发感染的风险
Life (Basel). 2023 May 28;13(6):1272. doi: 10.3390/life13061272.
5
Brentuximab vedotin induced uveitis.本妥昔单抗诱发了葡萄膜炎。
Am J Ophthalmol Case Rep. 2022 Feb 18;26:101440. doi: 10.1016/j.ajoc.2022.101440. eCollection 2022 Jun.
6
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.生物制剂和小分子靶向免疫调节治疗的感染并发症。
Clin Microbiol Rev. 2020 Jun 10;33(3). doi: 10.1128/CMR.00035-19. Print 2020 Jun 17.
7
Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).血液学和肿瘤学中免疫治疗和分子靶向药物相关感染。欧洲白血病感染会议(ECIL)立场文件。
Leukemia. 2019 Apr;33(4):844-862. doi: 10.1038/s41375-019-0388-x. Epub 2019 Jan 30.
Clin Cancer Res. 2012 Nov 1;18(21):5845-9. doi: 10.1158/1078-0432.CCR-12-1803. Epub 2012 Sep 7.
4
A novel role for reciprocal CD30-CD30L signaling in the cross-talk between natural killer and dendritic cells.CD30-CD30L 信号的相互作用在自然杀伤细胞和树突状细胞之间的串扰中发挥新作用。
Biol Chem. 2012 Jan;393(1-2):101-6. doi: 10.1515/BC-2011-213.
5
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.本妥昔单抗维迪昔(SGN-35)治疗复发或难治性系统性间变大细胞淋巴瘤患者的Ⅱ期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.
6
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.本妥昔单抗治疗异基因干细胞移植后复发的霍奇金淋巴瘤的安全性和疗效
Blood. 2012 Jul 19;120(3):560-8. doi: 10.1182/blood-2011-12-397893. Epub 2012 Apr 17.
7
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.一项评估 Brentuximab vedotin 治疗复发或难治性霍奇金淋巴瘤患者的关键性 II 期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.
8
NK cells protect secondary lymphoid tissue from cytomegalovirus via a CD30-dependent mechanism.自然杀伤细胞通过一种依赖CD30的机制保护次级淋巴组织免受巨细胞病毒感染。
Eur J Immunol. 2009 Oct;39(10):2800-8. doi: 10.1002/eji.200939508.
9
Synergistic OX40 and CD30 signals sustain CD8+ T cells during antigenic challenge.协同的OX40和CD30信号在抗原刺激期间维持CD8 + T细胞。
Eur J Immunol. 2009 Aug;39(8):2120-5. doi: 10.1002/eji.200939424.
10
Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.血液系统恶性肿瘤患者及异基因造血干细胞移植后巨细胞病毒、人疱疹病毒6型、人疱疹病毒7型和卡波西肉瘤疱疹病毒(人疱疹病毒8型)感染的管理
Bone Marrow Transplant. 2008 Aug;42(4):227-40. doi: 10.1038/bmt.2008.162. Epub 2008 Jun 30.